Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Camrelizumab-induced RCCEP
NCT06231680Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in reactive cutaneous capillary endothelial proliferation (RCCEP) (4 cohorts), sponsored by Henan Cancer Hospital. Primary endpoints: Incidence rate of RCCEP at 2 years and RCCEP response rate at 3 weeks. Started Jan 2024; status: recruiting.
02
Drugs
thalidomide
03
Conditions
reactive cutaneous capillary endothelial proliferation (RCCEP)
Beyond the preview
Go deeper on NCT06231680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231680.